Eli Lilly and Company (NYSE:LLY) Shares Sold by Lakeside Advisors INC.

Lakeside Advisors INC. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 677 shares of the company’s stock after selling 50 shares during the quarter. Lakeside Advisors INC.’s holdings in Eli Lilly and Company were worth $395,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Latitude Advisors LLC grew its position in Eli Lilly and Company by 4.9% during the fourth quarter. Latitude Advisors LLC now owns 1,274 shares of the company’s stock worth $743,000 after buying an additional 60 shares during the period. Tyche Wealth Partners LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth about $1,799,000. Arbor Trust Wealth Advisors LLC grew its position in Eli Lilly and Company by 7.6% during the fourth quarter. Arbor Trust Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $741,000 after buying an additional 90 shares during the period. HealthInvest Partners AB acquired a new position in Eli Lilly and Company during the fourth quarter worth about $9,213,000. Finally, Avior Wealth Management LLC grew its position in Eli Lilly and Company by 1.5% during the fourth quarter. Avior Wealth Management LLC now owns 4,935 shares of the company’s stock worth $2,877,000 after buying an additional 72 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LLY has been the topic of several research reports. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday. Bank of America increased their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.5 %

NYSE:LLY traded down $4.03 during trading hours on Wednesday, reaching $746.74. 2,569,799 shares of the company were exchanged, compared to its average volume of 2,215,511. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a market cap of $709.52 billion, a price-to-earnings ratio of 128.72, a PEG ratio of 1.64 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $367.35 and a 52-week high of $800.78. The stock has a 50 day simple moving average of $763.51 and a 200 day simple moving average of $657.01.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.